Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;15(7):357-365.

Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic

Vijay Pandyarajan  1 , Robert G Gish  1 , Naim Alkhouri  1 , Mazen Noureddin  1
Affiliations

Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic

Vijay Pandyarajan et al. Gastroenterol Hepatol (N Y). 2019 Jul.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of diseases ranging from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH) to advanced fibrosis and cirrhosis as well as liver cancer. Despite the significant morbidity associated with NAFLD, there are no global consensus guidelines to screen for liver fibrosis in patients considered high risk, including patients older than 50 years with type 2 diabetes or metabolic syndrome. Multiple therapies are currently being investigated and may soon receive regulatory approval for use in the clinic. It is suggested that patients at high risk for NAFLD be screened in the outpatient setting. This article aims to supply primary care providers (PCPs) with the knowledge and tools needed to properly evaluate a patient at high risk of developing significant liver disease from NASH. A tripartite algorithm is described to help PCPs identify patients with NAFLD using liver enzymes and abdominal ultrasound, assess the presence of advanced liver fibrosis using clinical prediction rules, and, if appropriate, determine when to refer patients to specialist care.

Keywords: Nonalcoholic fatty liver disease; ambulatory care; fatty liver; nonalcoholic steatohepatitis; outpatients; primary care; screening.

PubMed Disclaimer

Conflict of interest statement

Dr Alkhouri has received research funding from Gilead, Intercept, Genfit, and Allergan, and is a member of the speakers bureaus and advisory boards of Gilead and Intercept. Dr Noureddin has been on the advisory boards and/or has been a speaker for Echosens North America, OWL, Gilead, Intercept, Simply Speaking, Novartis, Blade, Allergan, and Abbott; has received research support from Gilead, Galmed, Galectin, Conatus, Enanta, Zydus, Novartis, BMS, Allergan, Genfit, and Shire; and is a minor shareholder of Anaetos and Viking. Dr Gish is a direct consultant for Viking and Intercept. Dr Pandyarajan has no relevant conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Suggested screening and treatment algorithm for NAFLD. ALT, alanine aminotransferase; FIB-4, Fibrosis-4; NAFLD, nonalcoholic fatty liver disease; NFS, NAFLD Fibrosis Score.
Figure 2.
Figure 2.
Suggested treatment for patients with different forms of fatty liver disease. HCC, hepatocellular carcinoma; NAFL, nonalcoholic fatty liver; NASH, nonalcoholic steatohepatitis.
See this image and copyright information in PMC

References

    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. - PubMed
    1. Younossi ZM, Stepanova M, Afendy M et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524–530.e1. - PubMed
    1. Setiawan VW, Stram DO, Porcel J, Lu SC, Le Marchand L, Noureddin M. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the Multiethnic Cohort. Hepatology. 2016;64(6):1969–1977. - PMC - PubMed
    1. Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–131. - PubMed
    1. Noureddin M, Vipani A, Bresee C et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113(11):1649–1659. - PMC - PubMed

LinkOut - more resources